Englander Institute for Precision Medicine

Publications

Found 692 results
Author Title [ Type(Desc)] Year
Journal Article
Galluzzi L, Aryankalayil MJ, C Coleman N, Formenti SC.  2023.  Emerging evidence for adapting radiotherapy to immunotherapy.. Nat Rev Clin Oncol.
Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
González-Muñoz T, Di Giannatale A, García-Silva S, Santos V, Sánchez-Redondo S, Savini C, Graña-Castro O, Blanco-Aparicio C, Fischer S, De Wever O et al..  2023.  Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.. Clin Cancer Res. 29(18):3744-3758.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Wechsler ME, Stephenson RE, Murphy AC, Oldenkamp HF, Singh A, Peppas NA.  2019.  Engineered microscale hydrogels for drug delivery, cell therapy, and sequencing.. Biomed Microdevices. 21(2):31.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP et al..  2020.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.. N Engl J Med. 382(23):2197-2206.
Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG et al..  2016.  The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.. Int J Mol Sci. 17(10)
Galassi C, Galluzzi L.  2023.  Epigenetic escape of immunosurveillance by malignant cell precursors.. EMBO J. 42(10):e114050.
Cheong J-G, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, Laurent P, Ma S, Paddock L, Miranda IC et al..  2023.  Epigenetic memory of coronavirus infection in innate immune cells and their progenitors.. Cell. 186(18):3882-3902.e24.
Lin T-Y, Ramsamooj S, Perrier T, Liberatore K, Lantier L, Vasan N, Karukurichi K, Hwang S-K, Kesicki EA, Kastenhuber ER et al..  2023.  Epinephrine inhibits PI3Kα via the Hippo kinases.. Cell Rep. 42(12):113535.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.
Pauli C, Moch H, Rubin MA.  2017.  [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].. Pathologe. 38(Suppl 2):160-168.
Romanel A, Zhang T, Elemento O, Demichelis F.  2017.  EthSEQ: ethnicity annotation from whole exome sequencing data.. Bioinformatics. 33(15):2402-2404.
Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, Moore AR, Wong EWP, Pachai MR, Xie Y et al..  2023.  ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.. Sci Adv. 9(14):eadc9446.
Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST.  2020.  An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.. Expert Opin Pharmacother. 21(8):863-870.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):91.
Purwada A, Shah SB, Béguelin W, August A, Melnick AM, Singh A.  2019.  Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells.. Biomaterials. 198:27-36.
Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XKathy, Ha T, Krumsiek J, Buyukozkan M, Verma A et al..  2021.  Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. Cancer Res. 81(9):2275-2288.
Huang FW, Mosquera JMiguel, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD et al..  2017.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations.. Cancer Discov. 7(9):973-983.
Rickman DS, Schulte JH, Eilers M.  2018.  The Expanding World of N-MYC-Driven Tumors.. Cancer Discov. 8(2):150-163.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN et al..  2023.  External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.. J Clin Oncol. 41(15):2736-2746.